HZ-H08905
/ HealZen Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 06, 2024
Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
(ASH 2024)
- "Monotherapy of HZ-H08905 was well tolerated and demonstrated significant efficacy in patients with R/R PTCL in phase I study. Currently, a randomized, double-blind, active-controlled phase 3 study is ongoing in China to evaluate HZ-H08905 in patients with R/R PTCL as a pivotal study."
Clinical • P1 data • Anemia • Cardiovascular • Chronic Lymphocytic Leukemia • Dermatitis • Dermatology • Diffuse Large B Cell Lymphoma • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Immunology • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Oncology • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • PIK3CD
November 06, 2024
Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
(ASH 2024)
- "Among the 12 patients with FL, the ORR was 83.3% (10/12) and CRR was 50.0% (6/12). Conclusions : These results demonstrated that HZ-H08905 monotherapy was well tolerated and showed significant efficacy in patients with R/R BCM, particularly R/R FL."
Clinical • P1 data • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Indolent Lymphoma • Infectious Disease • Leukopenia • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia • PIK3CD
November 03, 2023
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies
(ASH 2023)
- "These results demonstrated that HZ-H08905 monotherapy was well tolerated and showed promising efficacy in patients with R/R NHL. A Phase 2 R/R PTCL registration study in China is currently planned."
Clinical • P1 data • PK/PD data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Varicella Zoster • PIK3CD
April 02, 2025
A Double-blineded, Randomized, Multi-center Phase III Clinical Study of HZ-H08905 Versus Chidamide in Patients With Relapsed/Refractory PTCL
(ChiCTR)
- P3 | N=140 | Recruiting | Sponsor: Beijing Cancer Hospital/The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou HealZen Therapeutics Co., Ltd
New P3 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8
1 to 4
Of
4
Go to page
1